South San Francisco, Calif. and San Diego, Aug. 02, 2024 - ORIC Pharmaceuticals, a clinical-stage oncology company dedicated to developing innovative treatments that address mechanisms of therapeutic resistance, has recently announced the issuance of inducement grants under Nasdaq Listing Rule 5635(c)(4). These grants serve as a testament to ORIC’s commitment to attracting and retaining top talent within the competitive field of oncology research.
On August 1, 2024, ORIC granted a total of 33,000 non-qualified stock options and 5,600 restricted stock units to two new non-executive employees who recently joined the company in July of the same year. This move follows earlier inducement grants made by ORIC Pharmaceuticals on October 2, 2023. These grants included 72,120 non-qualified stock options and 12,040 restricted stock units, awarded to four non-executive employees who had joined ORIC in September 2023.
The cumulative net loss of $-93 million during the twelve-month period ending in the third quarter of 2023 may be viewed as a challenge faced by ORIC Pharmaceuticals. However, the company’s strategic approach to overcoming therapeutic resistance in oncology research shows promise for future growth and success. With these recent inducement grants, ORIC aims to align employee interests with the long-term goals of the company, fostering dedication and commitment, while simultaneously encouraging employee contributions toward ORIC’s mission.
As part of ORIC’s strategy to remain competitive, these equity-based incentives, including stock options and restricted stock units, provide tangible rewards that recognize employee expertise and drive. By attracting and retaining top talent, ORIC is positioning itself as a leading force in oncology breakthroughs.
The grants not only serve as a means of talent acquisition but also reflect the company’s determination to foster an environment that encourages innovation and commitment. ORIC Pharmaceuticals’ dedication to developing unique solutions for therapeutic resistance underscores their ambitious goals and commitment to leading advancements in oncology research.
By investing in its employees and ensuring that their incentives are aligned with the company’s long-term growth, ORIC Pharmaceuticals is poised for continued success in the competitive oncology landscape. The strategic inducement grants announced by ORIC demonstrate an astute understanding of the importance of talent acquisition and retention in driving breakthroughs in the field of oncology.
In conclusion, ORIC Pharmaceuticals’ recent inducement grants showcase their commitment to attracting and retaining top talent, reinforcing the company’s dedication to oncology breakthroughs. By aligning employee interests with long-term growth, ORIC provides the incentives necessary for its team to contribute their expertise and drive towards achieving the company’s mission. As ORIC continues to make strides in overcoming therapeutic resistance, these grants position it as a frontrunner in the competitive world of oncology research.
Comments